Germline mutations affecting G alpha(11) in hypoparathyroidism by Mannstadt, Michael et al.
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 368;26 nejm.org june 27, 20132532
of a meta-analysis of studies of the effect of re-
duced dietary salt on the incidence of cardiovas-
cular events and death.1 The authors of the Co-
chrane report wrote that there was “no strong 
evidence of benefit.” In a summary statement, we 
wrote that this particular Cochrane analysis con-
cluded that reducing dietary salt intake did not 
decrease the risk of death or cardiovascular dis-
ease. Stigler et al. suggest that “indeterminate 
results,” rather than no significant effect, would 
be a more appropriate interpretation of the analy-
sis. Both interpretations may be correct. Although 
it may not be possible to reject the null hypothe-
sis with certainty (i.e., no effect of reduced salt), 
the analysis should have been powered to detect 
a clinically meaningful difference, and the con-
clusion of no effect provides more guidance than 
“indeterminate results” to clinical decision mak-
ers. Focusing on these subtleties, however, miss-
es the point we made regarding the Cochrane re-
port. As analyzed by others2 and as cited in our 
review, after the exclusion of a trial involving pa-
tients with heart failure who received aggressive 
diuretic therapy and combining data for patients 
with and without hypertension, reduced salt in-
take was shown to be associated with a signifi-
cant reduction in the rate of cardiovascular 
events.
Thornton raises important questions: do rec-
ommended reductions of dietary sodium stimu-
late the renin–angiotensin–aldosterone axis, and 
does this in turn contribute to cardiovascular 
disease? In trials of abrupt and severe salt re-
striction, plasma renin activity and serum aldos-
terone levels were increased. Although long-
term, modest reductions in salt intake result in 
small, physiologic increases in plasma renin ac-
tivity,3 the preponderance of evidence suggests 
that a reduced salt intake is associated with a 
decreased risk of cardiovascular events and 
death. Furthermore, it is worth remembering 
that diuretics remain one of the most effective 
antihypertensive therapies, and their beneficial 
effect on cardiovascular disease is well docu-
mented.4 Nevertheless, as we suggested, in 
terms of safety, the lower limit of salt consump-
tion has not been clearly defined.
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Germline	Mutations	Affecting	Gα11	in	Hypoparathyroidism
To the Editor: Extracellular calcium levels are 
tightly regulated by parathyroid hormone (PTH). 
Insufficient production of this hormone, as ob-
served in nonsyndromic isolated hypoparathy-
roidism, can be caused by mutations in PTH or 
the genes encoding the parathyroid-specific 
transcription factor glial cells missing 2 (GCM2) 
or the calcium-sensing receptor (CaSR). However, 
most cases of isolated hypoparathyroidism re-
main genetically undefined.1
We investigated two unrelated white families 
in which 15 living members had clinical and 
laboratory findings consistent with autosomal 
dominant isolated hypoparathyroidism (Fig. 1). 
After ruling out the presence of mutations in 
CaSR, PTH, and GCM2 in the index cases (not 
shown), a genomewide scan revealed linkage 
to a single chromosomal region for Family A 
(19p13.3; LOD score, 3.0). Candidate gene se-
quencing resulted in the identification of a hetero-
zygous nucleotide change in exon 2 of GNA11 
(c.178C→T; p.Arg60Cys), the gene encoding the 
α subunit of the guanine nucleotide-binding 
protein G11 (Gα11) (Fig. S1 in the Supplementary 
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Appendix, available with the full text of this let-
ter at NEJM.org). Whole-exome sequencing of 
two affected members of Family A (Patients 37 
and 44) confirmed this nucleotide transition. 
Exome sequencing of two members of Family B 
(Patients 26 and 31) revealed a heterozygous 
nucleotide transversion in exon 5 of GNA11
(c.632C→G; p.Ser211Trp); no additional variant 
that affects the same gene in both families was 
identified. The nucleotide changes were present 
only in affected family members, and both 
changes affect amino acid residues that are 
highly conserved in Gα11 and the closely relat-
ed Gαq.
Gα11 and Gαq mediate the intracellular sig-
naling that depends on the generation of inositol 
1,4,5-trisphosphate and the activation of protein 
kinase C and occurs downstream of CaSR,2 the 
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Figure	1.	Pedigrees	and	Laboratory	and	Genetic	Findings	for	Two	Families	with	Autosomal	Dominant	Isolated	Hypoparathyroidism.
Squares indicate male family members, circles female family members, black symbols affected family members, and white symbols un-
affected family members; slashes indicate deceased family members; numbers outside squares and circles indicate family members for 
whom DNA was available for testing; numbers within white rhombi indicate the number of unaffected siblings. Arrows point to the index 
cases. Measurements for calcium, phosphorus, and parathyroid hormone (PTH) are shown (with adult normal ranges in parentheses) 
and reflect values at presentation except in the case of Patients 21 and 32, from whom samples were drawn after treatment was initiated. 
For affected members, mean (±SE) pretreatment serum levels of calcium were 2.15±0.02 mmol per liter in Family A and 1.91±0.04 mmol 
per liter in Family B, mean levels of phosphorus were 2.06±0.40 and 1.79±0.13 mmol per liter, respectively, and mean levels of PTH were 
1.97±0.42 and 1.33±0.27 pmol per liter, respectively. Values for other variables among patients with autosomal dominant isolated hypo-
parathyroidism for whom mean pretreatment levels were available were as follows: magnesium, 0.77±0.02 mmol per liter (10 patients; 
normal range, 0.7 to 1.0); 1,25-dihydroxyvitamin D, 81.8±10.0 pmol per liter (8 patients; normal range, 40 to 150); and urinary calcium:creatinine 
ratio, normal when measured (8 patients; normal range, <0.6 mmol:mmol). Two novel mutations affecting Gα11 (R60C and S211W) 
were identified by means of genetic linkage analysis for Family A and exome sequencing of a DNA sample from two affected members 
of Families A and B (see Fig. 1 in the Supplementary Appendix). Digestion of DNA (amplified by means of polymerase chain reaction) 
with the endonucleases FspI and BsiEI, respectively, confirmed the two mutations and revealed their segregation with the disease. 
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main regulator of PTH synthesis and secretion. 
Homozygous inactivating CaSR mutations cause 
severe neonatal hyperparathyroidism, as does the 
combined parathyroid-specific ablation of Gα11 
and Gαq in mice.3,4 Conversely, activating CaSR 
mutations lead to hypocalcemia because of inap-
propriate PTH secretion.1 The latter findings 
are similar to those reported for our families 
with autosomal dominant isolated hypoparathy-
roidism, thus making it plausible to suggest that 
the identified Gα11 mutants increase signaling 
at this receptor.
To evaluate this hypothesis, we analyzed both 
mutants with the use of molecular modeling 
(Fig. S2 in the Supplementary Appendix). On the 
basis of the proposed crystal structure of Gα11, 
it is probable that the replacement of arginine 60 
with cysteine (R60C mutant) in helix α1 of the 
guanosine triphosphatase (GTPase) domain will 
disrupt the intramolecular hydrogen bond with 
asparagine 71, located in αA of the helical do-
main. This mutant is therefore predicted to de-
stabilize the “closed clamshell” conformation of 
the helical and GTPase domains, thus allowing 
either a faster exchange of guanosine diphos-
phate with GTP or disrupting Gα11 contacts with 
regulatory proteins. In contrast, the replacement 
of serine 211 in the switch II region of Gα11 with 
tryptophan (S211W mutant) is predicted to dis-
rupt the binding of the mutant α subunit to the 
β subunit, thereby enhancing agonist-dependent 
signaling.
Activating mutations affecting Gα11 and Gαq 
cause uveal melanomas5; however, these genetic 
changes are somatic, as are most disease-causing 
mutations in other G proteins (Table S1 in the 
Supplementary Appendix). In fact, only a few 
activating germline mutations affecting G pro-
teins appear to be compatible with life; these 
include maternal mutations affecting Gαs that 
cause gonadotropin-independent male precocious 
puberty or neonatal diarrhea in combination 
with pseudohypoparathyroidism type 1a, and 
three murine germline mutations affecting Gαq 
or Gα11 that lead to dermal hyperpigmentation. 
The inherited mutations affecting Gα11 in family 
members with autosomal dominant isolated hy-
poparathyroidism are therefore remarkable, par-
ticularly since obvious abnormalities affect only 
the regulation of mineral-ion homeostasis. In 
summary, genomewide linkage analysis, com-
bined with whole-exome sequencing, revealed 
two different heterozygous mutations affecting 
Gα11 as novel causes of autosomal dominant 
isolated hypoparathyroidism.
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